This new approval expands Ozempic’s use, adding to its previous indications for improving glycemic control in Type 2 diabetes and reducing major cardiovascular events in people with heart disease, according to a Jan. 28 news release from Novo Nordisk.
The basis of the approval was due to a phase 3 trial that demonstrated the drug significantly reduced the risk of kidney disease progression and cardiovascular death by 24%, compared to a placebo, over three years.
Ozempic was first approved by the FDA in 2017 for blood sugar control in Type 2 diabetes. It received a cardiovascular indication in 2020 and is now the most broadly indicated GLP-1 receptor agonist for managing diabetes, kidney disease and heart risk.
